Hans van Houte - 10 Feb 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Reporting relationship: Chief Financial Officer
Issuer ticker: NRIX
Reported as of: 10 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Feb 2026, 18:09:29 UTC
Prior SEC filing: 30 Jan 2026
Next SEC filing: 30 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte

Key filing fact

Hans van Houte filed Form 4 for Nurix Therapeutics, Inc. (NRIX) on 10 Feb 2026.

Key facts

This page summarizes Hans van Houte's Form 4 filing for Nurix Therapeutics, Inc. (NRIX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Feb 2026, 18:09.

Change

Previous filing in this sequence was filed on 30 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001817217 Primary reporting owner

van Houte Hans

Relationship: Chief Financial Officer
Address: C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE
Signature: /s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte
Signature date: 10 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NRIX transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +93,750
Change %
Price: $0.000000
Shares after: 93,750
Date: 10 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 93,750
Exercise price: $16.45
Footnotes: F1

NRIX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +42,875
Change %
Price: $0.000000
Shares after: 42,875
Date: 10 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,875
Exercise price: $0.000000
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F2

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Footnote F4

RSUs do not expire; they either vest or are canceled prior to the vest date.